Does semaglutide help heart failure?

For a specific group, trials suggest it may help people feel and function better. STEP-HFpEF and STEP-HFpEF DM enrolled people with symptoms, obesity, and preserved or nearly preserved ejection fraction. They reported better symptom scores, longer six-minute walking distance, and greater weight loss with semaglutide than placebo. They did not establish that semaglutide prevents death.

Which heart-failure patients are covered by the 2026 ESC recommendation?

The recommendation covers people with symptomatic heart failure, a left-ventricular ejection fraction of at least 45%, and a BMI of at least 30, regardless of diabetes status. The ESC table labels this Class IIa, Level B1. It is a treatment to consider with a cardiologist, not an automatic choice for everyone who meets those numbers.

Does semaglutide reduce heart-failure deaths?

That has not been established. The two STEP-HFpEF trials were built to measure symptoms, physical limitations, walking distance, and weight over one year, not mortality. SUMMIT found fewer worsening heart-failure events with tirzepatide, but only 13 cardiovascular deaths occurred across both groups, too few to show a mortality benefit.

Is semaglutide approved for heart failure in the United States?

No. The current U.S. Wegovy label does not list heart failure as an indication. It does include cardiovascular-risk reduction for adults who already have cardiovascular disease and also have obesity or overweight, but that comes from the SELECT population, not the STEP-HFpEF population. A guideline recommendation and a U.S. labeled indication are different things.

Can compounded semaglutide be assumed to have the same heart-failure results?

No assumption is justified because the compounded formulation offered through Promise was not used in the STEP-HFpEF trials. A licensed provider may still prescribe a compounded formulation after reviewing the individual patient, but heart failure calls for coordination with a cardiologist. The decision belongs to the patient and treating clinicians, not to a headline or a dosing guide.

Semaglutide for Heart Failure Now Has ESC Support

Semaglutide for heart failure now has guideline support in Europe, but only for a particular group: people with symptoms, obesity, and an ejection fraction—the share of blood the heart's main pumping chamber pushes out with each beat—of at least 45%. The new recommendation is mostly about feeling and functioning better—less symptom burden, greater walking capacity, and weight loss. It isn't proof that semaglutide prevents death from heart failure, and it isn't a reason to start it without a cardiologist.

What changed for semaglutide for heart failure

As of September 6, 2026, the day this article was written, the newest major development is the European Society of Cardiology guideline published on August 28. Its recommendation table says semaglutide or tirzepatide should be considered for people with symptomatic heart failure, a left-ventricular ejection fraction of at least 45%, and a body mass index of at least 30, whether or not they have diabetes.

Body mass index, or BMI, relates weight to height. HFpEF means heart failure with preserved ejection fraction: the squeeze looks near normal, yet the heart is too stiff or pressured to fill and work normally.

The table prints the recommendation as Class IIa, Level B1. In everyday language, Class IIa is a qualified yes: the panel says the treatment should be considered, not that every person who meets the thresholds should receive it. Level B1 means suggestive, not conclusive, evidence, usually from at least one adequately powered randomized trial. The ESC's August 28 release highlights the same change.

This wasn't a Europe-only conversation. A July 23, 2026, American College of Cardiology expert pathway said semaglutide or tirzepatide may be prescribed for people with HFpEF and a BMI of at least 30 to improve health status and exercise function and potentially reduce worsening heart-failure events. That is expert guidance, not a new U.S. drug indication.

What the trials actually found

The semaglutide evidence comes from two one-year randomized trials. Randomized means people were assigned by chance to semaglutide or a placebo, a look-alike treatment without semaglutide, which makes the comparison more trustworthy.

In the 2023 STEP-HFpEF trial, 529 adults had heart failure, an ejection fraction of at least 45%, and a BMI of at least 30, without diabetes. The study used semaglutide 2.4 mg once weekly.

After 52 weeks, scores on a 100-point symptom and physical-limitation scale rose 16.6 points with semaglutide and 8.7 with placebo, a 7.8-point difference. Participants receiving semaglutide also walked about 20 metres farther than the placebo group in six minutes. Average weight change differed by 10.7 percentage points between the groups.

The 2024 STEP-HFpEF DM trial asked the same basic question in 616 people who also had type 2 diabetes. The between-group difference was 7.3 points on the symptom scale and 14.3 metres on the six-minute walk. Average weight change differed by 6.4 percentage points.

Those are useful, human outcomes: breathing, stamina, daily limits, and weight. Neither STEP trial was designed to establish that semaglutide prevents heart-failure hospitalization or death.

Why tirzepatide appears beside semaglutide

The 731-person SUMMIT trial studied tirzepatide in people with HFpEF and obesity, with participants followed for about two years. Cardiovascular death or a worsening heart-failure event occurred in 36 of 364 people receiving tirzepatide, about 1 in 10, and 56 of 367 receiving placebo, about 1 in 7. The gap was driven mainly by fewer worsening heart-failure events. With only 13 cardiovascular deaths across both groups, the trial did not establish that tirzepatide prevents death.

SUMMIT also reported a 6.9-point advantage on the symptom scale and an 18.3-metre advantage in the six-minute walk. That mix of daily-life measures and event data helps explain why the guideline names both medicines.

What the recommendation does not mean

It does not turn semaglutide into a treatment for every kind of heart failure. The trial populations had symptoms, obesity, and preserved or nearly preserved pumping function. Results from that group can't simply be carried over to someone with a markedly reduced ejection fraction or a different reason for heart failure.

The current U.S. Wegovy label does not list heart failure as an indication. Its cardiovascular indication concerns adults with established cardiovascular disease and obesity or overweight—a different population studied in SELECT. The broader semaglutide and heart health guide covers that story.

The formulations matter too. Semaglutide offered through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The compounded formulation was not used in STEP-HFpEF or STEP-HFpEF DM. Compounded semaglutide explains that distinction in more detail.

FDA status is not a marketing gate: a licensed provider may still prescribe a compounded formulation, and that decision is between the patient and the doctor. The new recommendation also does not replace the other medicines and monitoring that a cardiologist uses for heart failure.

How a cardiologist makes the decision

A clinician first has to confirm that the symptoms really come from HFpEF. Shortness of breath and swollen ankles can have other causes. An echocardiogram, which is an ultrasound picture of the heart, shows pumping function but is only part of that diagnosis.

The discussion then becomes practical: current heart medicines, kidney function, blood pressure, diabetes treatment, symptoms, and whether obesity is part of the heart-failure picture. The Wegovy label warns about acute kidney injury from volume depletion—kidney strain caused by losing too much fluid after nausea, vomiting, or diarrhea. That matters when someone is also taking a diuretic, a medicine that helps the body release extra fluid. The fuller semaglutide side-effects guide explains the usual safety conversation.

At Promise, a licensed provider reviews every request and not everyone qualifies. With heart failure in the picture, the prescribing clinician and cardiologist should be working from the same medication list and the same plan.

What to watch next

The next useful evidence will be longer follow-up and semaglutide trials designed to count worsening heart-failure events, hospitalizations, and deaths—not only symptoms and walking distance. Until then, the guideline change is meaningful but narrow: semaglutide has entered the treatment conversation for a defined group with heart failure and obesity. It has not become a universal heart-failure medicine.